Schedule I in US; FDA rejected Lykos NDA August 2024; Transcend/Otsuka methylone analog in Phase 3
Reporting + research wiki
Psychedelics as a reported story and a living record.
Spare Change of Mind tracks psychedelic medicine across trials, companies, regulators, history, and consciousness, with an editorial front end backed by a growing research wiki built for citations, entity linking, and context that compounds.
There is something a little odd about asking an AI to help keep careful notes on one of the strangest stories in medicine. That is part of the experiment here. The bar is still the same: make it readable, make it sourced, and make it useful.
Follow the reporting as it lands.
Start with the archive to track the latest stories across trials, companies, regulators, and psychedelic history.
Primary research surface
Start with the recurring entities and institutions behind the coverage.
Schedule I in US; approved in Australia for TRD and PTSD; extensive Phase 2/3 trials globally
Seeking Phase 3 redesign following FDA Complete Response Letter (August 2024)
Active regulator for multiple psychedelic INDs; midomafetamine NDA reviewed in June 2024 and later rejected via Complete Response Letter
Active nonprofit research and policy organization; MDMA-assisted therapy remains investigational and MAPS continues public education and program context
Use the wiki as a map of companies, compounds, concepts, and regulators.
Follow the dossiers that moved most recently.
Active regulator for multiple psychedelic INDs; midomafetamine NDA reviewed in June 2024 and later rejected via Complete Response Letter
Deceased; pediatrician, co-author, and under-described figure in mushroom history
Deceased; enduring counterculture symbol and reference point in psychedelic history
Deceased; psychedelic philosopher, writer, speaker, and archival subject
Latest reporting
Where MAPS Is Now
After the FDA rejected Lykos' MDMA therapy application, MAPS shifted toward policy, education, and the long game.
The best-supported answer still begins at 5-HT2A, but the downstream story on plasticity and biomarkers is much less settled.
First full week roundup.
Cybin's CYB003 program is recruiting in phase 3, Mount Sinai is running an MDMA therapist-training study, Brigham has a severe alcohol use disorder protocol queued up, and smaller psilocybin studies in OCD and antidepressant interaction remain active.
Indiana University has posted a not-yet-recruiting psilocybin protocol for veterans and first responders with treatment-resistant depression and co-occurring substance use disorder. Johns Hopkins' OCD study is active but no longer recruiting. UC Irvine is recruiting an ibogaine neuroimaging study in opioid use disorder.
Oregon's regulated psilocybin program is real and growing, while Washington's SB 5921 remains stuck in committee.
How Richard Alpert became Ram Dass, why Be Here Now mattered, and how his path diverged from Timothy Leary's while still sharing psychedelic roots.